A Phase 2 interventional study of Capecitabine and Radiation therapy in Brainstem Glioma, sponsored by Hoffmann-La Roche. Completed at 8 sites in United States. Open to participants aged 3 Years to 17 Years. Per ClinicalTrials.gov, last updated 2014-02-06.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluated the effect of capecitabine and concomitant radiation therapy in children with newly diagnosed brainstem gliomas.
The open-label phase 2 study NO21125 (NCT01118377) evaluated the progression-free survival, safety, and pharmacokinetics of capecitabine (Xeloda®) rapidly disintegrating tablets and concomitant radiation therapy in children and adolescent patients with newly diagnosed brainstem glioma. There were 2 phases to the study: A 9-week radiation phase, followed by a 2-week rest period, and a 9-week post-radiation phase. In the radiation phase, capecitabine 650 mg/m\^2 was administered orally twice daily for 9 weeks. Concomitantly, patients received radiation therapy (180 cGy fractions) 5 days a week for a total target dose of 56 Gy. During the 9-week post-radiation phase of the study, capecitabine 1250 mg/m\^2 was administered orally twice daily for 14 days followed by a 7-day rest period. This cycle of 14 days treatment followed by 7 days rest was repeated 2 additional times. The dose could be adjusted according to toxicity and body surface area.
The single-arm phase 1 study NO18517 (NCT00532948) assessed the maximum tolerated dose and dose-limiting toxicities of capecitabine (Xeloda®) administered concurrently with radiation therapy in children with newly diagnosed diffuse intrinsic brain stem gliomas and high grade gliomas. Patients in the phase 1 study NO18517 who were diagnosed with intrinsic brainstem glioma and who were treated at the established maximum tolerated dose of capecitabine 650 mg/m\^2/dose twice a day were included in the analyses of the phase 2 study NO21125.
The efficacy and safety results of study NO21125 are reported below.
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 9 weeks of capecitabine 650 mg/m\^2 orally (po) twice daily (bid) plus radiation therapy (180 cGy/day 5 days a week, total target dose of 56 Gy) followed by a 2-week rest period. Participants then received 3 cycles of capecitabine 1250 mg/m\^2 po bid for 14 days followed by a 7-day rest period without radiation therapy.
Drug: Capecitabine · Radiation: Radiation therapy
Capecitabine was supplied as film-coated tablets.
Also known as: Xeloda
Local irradiation using conformal, volume-based delivery techniques. The nominal energy of the X-rays was ≥ 4 MV.
Progression-free Survival
Progression-free survival was defined as the time from the initiation of treatment to the earliest date of failure (disease progression, death from any cause, or a second malignancy) or to the last assessment date for patients who did not fail. Disease progression was defined as progressive neurologic abnormalities or worsening neurologic status not explained by causes unrelated to tumor progression (eg, anticonvulsant or corticosteroid toxicity, electrolyte disturbances, sepsis, hyperglycemia, weaning of steroids, radiation necrosis, etc); or a greater than 25% increase in the bi-dimensional measurement of the tumor, as compared with the previous scan; or the appearance of a new lesion; or an increase in the doses of dexamethasone required to maintain stable neurologic status or imaging.
Time frame: Baseline to the end of the study (up to 20 weeks)
Overall Survival
Overall survival was defined as the time from the initiation of therapy to the date of death from any cause or to the date the patient was last known to be alive for surviving patients.
Time frame: Baseline to the end of the study (up to 20 weeks)
Percentage of Participants With a Tumor Response
Tumor response was defined as either a complete response or a partial response prior to failure (disease progression, death from any cause, or a second malignancy). A complete response was defined as the complete disappearance on magnetic response imaging of all enhancing tumor and mass effect on a stable or decreasing dose of dexamethasone (or only receiving adrenal replacement doses) accompanied by a stable or improving neurologic examination that was maintained for at least 12 weeks. A partial response was defined as a greater than or equal to 50% reduction in tumor size by bi-dimensional measurement on a stable or decreasing dose of dexamethasone accompanied by a stable or improving neurologic examination that was maintained for at least 12 weeks.
Time frame: Baseline to the end of the study (up to 20 weeks)
| Milestone | Capecitabine + Radiation Therapy |
|---|---|
| Started | 45 |
| Completed | 3 |
| Not completed | 42 |
| Withdrew: Did not receive study medication | 1 |
| Withdrew: Death | 38 |
| Withdrew: Failure to return | 3 |
Progression-free survival was defined as the time from the initiation of treatment to the earliest date of failure (disease progression, death from any cause, or a second malignancy) or to the last assessment date for patients who did not fail. Disease progression was defined as progressive neurologic abnormalities or worsening neurologic status not explained by causes unrelated to tumor progression (eg, anticonvulsant or corticosteroid toxicity, electrolyte disturbances, sepsis, hyperglycemia, weaning of steroids, radiation necrosis, etc); or a greater than 25% increase in the bi-dimensional measurement of the tumor, as compared with the previous scan; or the appearance of a new lesion; or an increase in the doses of dexamethasone required to maintain stable neurologic status or imaging.
| Months | Capecitabine + Radiation Therapy |
|---|---|
| Progression-free Survival | 4.9 (4.5 to 6.0) |
Overall survival was defined as the time from the initiation of therapy to the date of death from any cause or to the date the patient was last known to be alive for surviving patients.
| Months | Capecitabine + Radiation Therapy |
|---|---|
| Overall Survival | 10.3 (7.7 to 12.9) |
Tumor response was defined as either a complete response or a partial response prior to failure (disease progression, death from any cause, or a second malignancy). A complete response was defined as the complete disappearance on magnetic response imaging of all enhancing tumor and mass effect on a stable or decreasing dose of dexamethasone (or only receiving adrenal replacement doses) accompanied by a stable or improving neurologic examination that was maintained for at least 12 weeks. A partial response was defined as a greater than or equal to 50% reduction in tumor size by bi-dimensional measurement on a stable or decreasing dose of dexamethasone accompanied by a stable or improving neurologic examination that was maintained for at least 12 weeks.
| Percentage of participants | Capecitabine + Radiation Therapy |
|---|---|
| Percentage of Participants With a Tumor Response | 2.3 (0.1 to 12.0) |
Collected over Adverse events were reported from Baseline up to 30 days after the last treatment (up to 24 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Capecitabine + Radiation Therapy | — | 23/44 (52.3%) | 44/44 (100%) |
| Event | Capecitabine + Radiation Therapy |
|---|---|
| Neutrophil count decreasedInvestigations | 5/44 |
| Central nervous system necrosisNervous system disorders | 3/44 |
| HydrocephalusNervous system disorders | 3/44 |
| ConvulsionNervous system disorders | 2/44 |
| Neurological symptomNervous system disorders | 2/44 |
| Disease progressionGeneral disorders | 2/44 |
| PyrexiaGeneral disorders | 2/44 |
| White blood cell count decreasedInvestigations | 2/44 |
| DiarrhoeaGastrointestinal disorders | 2/44 |
| DysphagiaGastrointestinal disorders | 2/44 |
| Event | Capecitabine + Radiation Therapy |
|---|---|
| VomitingGastrointestinal disorders | 35/44 |
| Alanine aminotransferase increasedInvestigations | 33/44 |
| Lymphocyte count decreasedInvestigations | 32/44 |
| White blood cell count decreasedInvestigations | 27/44 |
| Platelet count decreasedInvestigations | 25/44 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 21/44 |
| HeadacheNervous system disorders | 20/44 |
| HypokalaemiaMetabolism and nutrition disorders | 18/44 |
| FatigueGeneral disorders | 18/44 |
| HypocalcaemiaMetabolism and nutrition disorders | 17/44 |
Intent-to-treat population: All enrolled participants who received at least 1 dose of capecitabine. One of the 45 participants did not receive treatment and was not included in the intent-to-treat population (34 participants from study NO21125 and 10 participants from study NO18517).
| Age, Continuous(years) | Capecitabine + Radiation Therapy |
|---|---|
| Mean | 7.5 ± 3.69 |
| Sex: Female, Male(Participants) | Capecitabine + Radiation Therapy |
|---|---|
| Female | 22 |
| Male | 22 |
The record gives a start of May 2007, a primary completion of Jan 2013 and a completion of Apr 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2013, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Capecitabine